Speech-Language Pathologists in East Haven, CT Accepting Medicare
9 Speech-Language Pathologists found. Showing 1 - 9
 Mrs. Rebecca Catherine Fasulo, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 35 Wheelbarrow Ln, East Haven, CT 06513 Phone: 203-468-3261 |
Angela Mack Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5 Walter St, East Haven, CT 06512 Phone: 203-907-8885 |
Maegan Anabel Onofrio Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10 S Dale St, East Haven, CT 06513 Phone: 203-687-8892 |
Caitlyn Black Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 451 N High St, East Haven, CT 06512 Phone: 203-466-6580 |
Dominique Paula Izzo Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 Sylvan Hills Rd, East Haven, CT 06513 Phone: 203-871-7985 |
Stephanie Anne Herndon, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 38 Talmadge Ave, East Haven, CT 06512 Phone: 203-469-2316 |
Kristina Detweiler Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 140 Mill St Apt 18134, East Haven, CT 06512 Phone: 037-571-3202 |
Miss Lindsey Erin Dagata, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 451 N High St, East Haven, CT 06512 Phone: 203-466-6850 Fax: 203-466-5848 |
Miss Jaime M Buley Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 451 N High St, East Haven, CT 06512 Phone: 203-466-6850 |
News Archive
Scientists identify TDO enzyme as new target for cancer therapy
Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors.
Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.
New findings into the biology of progressive hearing loss
New research with funding from UK charity Action on Hearing Loss has led to the discovery of a new biological mechanism involved in the progressive loss of hearing which could lead to new approaches to treating this common form of hearing loss.
Some public health experts raise concerns over plans to immunize Haitians against cholera, AP reports
The Associated Press/Washington Times reports on a pilot project plan by Partners In Health (PIH) and GHESKIO to vaccinate Haitians against cholera, which "has set off a debate among some public health experts who question the wisdom of the program that will inoculate only one percent of the population and could deplete the world's stock of available cholera vaccine, potentially putting people at risk in other vulnerable places."
› Verified 9 days ago
Physical Therapists
Chiropractors
Speech-Language Pathologists
Podiatrists
Optometrists
Occupational Therapists